Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib with Carboplatin and Paclitaxel in Advanced Solid Tumors
NCT02317874Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (advanced stage) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose of talazoparib three day schedule at 21 days and Maximum tolerated dose and recommended phase 2 dose of talazoparib seven day schedule at 21 days. Started Sep 2015; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02317874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317874.